Study finds Novo Nordisk's Ozempic may reduce dementia
The study looked at semaglutide, the scientific name for Novo Nordisk's NVO, -2.07% NOVO.B, +0.52% Ozempic, with the intent of looking at whether it caused neurological problems. Instead, it found a 48% decline in dementia relative to those who took sitagliptin, Merck's diabetes drug that's known as Januvia.
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.
US FDA declines to approve Novo Nordisk's weekly insulin
The U.S. Food and Drug Administration has declined to approve Novo Nordisk's weekly insulin in patients with diabetes, the Danish drugmaker said on Wednesday.
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices
Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk can be convinced to cut the U.S. prices of its popular Ozempic and Wegovy used for weight loss by publicly shaming the drugmaker over how much it charges compared to prices in other countries.
Novo Nordisk, Indonesia's Bio Farma sign deal to produce insulin
Danish drugmaker Novo Nordisk has signed a deal with Indonesia's state-owned pharmaceutical company Bio Farma to produce insulin to combat diabetes in the Southeast Asian country, a Bio Farma senior official said on Wednesday.
Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drug
Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy, were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to faster and greater weight loss.
Eli Lilly weight-loss drug found more effective than Novo Nordisk's Ozempic
Novo Nordisk (NYSE:NVO) shares fell and Eli Lilly and Co (NYSE:LLY) rose after a study found the US company's weight-loss drug may be more effective. Lilly's tirzepatide, branded as Mounjaro, was pitted against semaglutide, which Novo Nordisk (NYSE:NVO) makes under the Wegovy higher-dose brand for weight loss and Ozempic for type-2 diabetes, though the patients in the trial were all taking Ozempic.
Imperial College spin-out Myricx Bio lands £90m of new investment
An Imperial College spin-out has landed £90 million in Series-A funding backed by heavyweight investors, including an offshoot of the British Business Bank (BBB). Myricx Bio, the recipient of this funding, is at the forefront of developing innovative cancer treatments.
Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector
Danish drugmaker Novo Nordisk has been reprimanded by UK regulators for failing to disclose fees and expenses paid to individuals and organisations in Britain amounting to about 7.8 million pounds ($9.97 million) between 2020 and 2022.
Is It Too Late to Buy Novo Nordisk Stock?
Novo Nordisk's valuation is high, and the U.S. patent for semaglutide expires in early 2026. However, the drugmaker has a promising pipeline that could drive growth for years to come.
Novo Nordisk shares drop as study links drugs to vision loss
Novo Nordisk (NYSE:NVO) shares have dropped by close to 4% this week, shedding more than £350 billion from its market cap, after a study suggested there may be a link between its blockbuster weight loss drugs Wegovy and Ozempic and vision loss. Those who have been prescribed the weight-loss injection are at a higher risk of developing an eye condition linked to blindness, the study said.
